Browsing by Author "Nedeljkovic, Nadezda (7003443312)"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production(2008) ;Lavrnja, Irena (8976505900) ;Stojkov, Danijela (13906406300) ;Bjelobaba, Ivana (13906035700) ;Pekovic, Sanja (6602339917) ;Dacic, Sanja (6701736513) ;Nedeljkovic, Nadezda (7003443312) ;Mostarica-Stojkovic, Marija (6701741422) ;Stosic-Grujicic, Stanislava (7004253020) ;Rakic, Ljubisav (57225206280)Stojiljkovic, Mirjana (7003831351)To determine the mechanism underlying ribavirin induced amelioration of experimental autoimmune encephalomyelitis (EAE), cytokine profiles were evaluated in draining lymph node (DLN) cell culture supernatants and spinal cord obtained from EAE and/or ribavirin-treated EAE Dark Agouti rats. Administration of ribavirin to EAE rats markedly affected the production of pro-inflammatory cytokines IFN-γ, IL-1β and TNF-α in DLN and spinal cord, thus shifting the balance towards the anti-inflammatory cytokines IL-10 and TGF-β. These findings suggest that ribavirin attenuates EAE by limiting cytokine-mediated immunoinflammatory events leading to CNS destruction. The conducted experiments provide rationale for ribavirin to be considered as a candidate drug in the development of new therapeutic strategies for the treatment of autoimmune diseases in humans, such as multiple sclerosis. © 2008 Elsevier B.V. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production(2008) ;Lavrnja, Irena (8976505900) ;Stojkov, Danijela (13906406300) ;Bjelobaba, Ivana (13906035700) ;Pekovic, Sanja (6602339917) ;Dacic, Sanja (6701736513) ;Nedeljkovic, Nadezda (7003443312) ;Mostarica-Stojkovic, Marija (6701741422) ;Stosic-Grujicic, Stanislava (7004253020) ;Rakic, Ljubisav (57225206280)Stojiljkovic, Mirjana (7003831351)To determine the mechanism underlying ribavirin induced amelioration of experimental autoimmune encephalomyelitis (EAE), cytokine profiles were evaluated in draining lymph node (DLN) cell culture supernatants and spinal cord obtained from EAE and/or ribavirin-treated EAE Dark Agouti rats. Administration of ribavirin to EAE rats markedly affected the production of pro-inflammatory cytokines IFN-γ, IL-1β and TNF-α in DLN and spinal cord, thus shifting the balance towards the anti-inflammatory cytokines IL-10 and TGF-β. These findings suggest that ribavirin attenuates EAE by limiting cytokine-mediated immunoinflammatory events leading to CNS destruction. The conducted experiments provide rationale for ribavirin to be considered as a candidate drug in the development of new therapeutic strategies for the treatment of autoimmune diseases in humans, such as multiple sclerosis. © 2008 Elsevier B.V. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: Clinical and histopathological evaluation(2008) ;Stojkov, Danijela (13906406300) ;Lavrnja, Irena (8976505900) ;Pekovic, Sanja (6602339917) ;Dacic, Sanja (6701736513) ;Bjelobaba, Ivana (13906035700) ;Mostarica-Stojkovic, Marija (6701741422) ;Stosic-Grujicic, Stanislava (7004253020) ;Jovanovic, Sasa (57196922314) ;Nedeljkovic, Nadezda (7003443312) ;Rakic, Ljubisav (57225206280)Stojiljkovic, Mirjana (7003831351)Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS) and the helpful tool in preclinical testing of various substances considered for treatment of this human CNS disease. Ribavirin (R) and tiazofurin (T) are purine nucleoside analogues, with the broad spectrum of anti-viral, anti-tumoral and anti-inflammatory properties. We proposed that combined treatment with RT, administrated during the effector phase of EAE, would attenuate disease severity, both clinically and pathologically. Ribavirin was given daily at a dosage of 30 mg/kg and tiazofurin was given at a dosage of 10 mg/kg every other day for 15 days. We detected amelioration of clinical signs and faster recovery in the RT group compared to the control group. Immunohistochemical analyses revealed that RT treatment decrease the number of T cells, macrophages and microglia. In the controls, we detected reactive type of microglia, while in the RT group we noticed ramified/resting form. Demyelination areas and axonal damage were not recorded in the RT group, in contrast to the control group where multiple areas of demyelination zones and axonal loss were found. RT combination treatment suppresses ongoing EAE, prevents demyelination and axonal loss, and therefore may well be the potential therapy for the treatment of MS. © 2007 Elsevier B.V. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: Clinical and histopathological evaluation(2008) ;Stojkov, Danijela (13906406300) ;Lavrnja, Irena (8976505900) ;Pekovic, Sanja (6602339917) ;Dacic, Sanja (6701736513) ;Bjelobaba, Ivana (13906035700) ;Mostarica-Stojkovic, Marija (6701741422) ;Stosic-Grujicic, Stanislava (7004253020) ;Jovanovic, Sasa (57196922314) ;Nedeljkovic, Nadezda (7003443312) ;Rakic, Ljubisav (57225206280)Stojiljkovic, Mirjana (7003831351)Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS) and the helpful tool in preclinical testing of various substances considered for treatment of this human CNS disease. Ribavirin (R) and tiazofurin (T) are purine nucleoside analogues, with the broad spectrum of anti-viral, anti-tumoral and anti-inflammatory properties. We proposed that combined treatment with RT, administrated during the effector phase of EAE, would attenuate disease severity, both clinically and pathologically. Ribavirin was given daily at a dosage of 30 mg/kg and tiazofurin was given at a dosage of 10 mg/kg every other day for 15 days. We detected amelioration of clinical signs and faster recovery in the RT group compared to the control group. Immunohistochemical analyses revealed that RT treatment decrease the number of T cells, macrophages and microglia. In the controls, we detected reactive type of microglia, while in the RT group we noticed ramified/resting form. Demyelination areas and axonal damage were not recorded in the RT group, in contrast to the control group where multiple areas of demyelination zones and axonal loss were found. RT combination treatment suppresses ongoing EAE, prevents demyelination and axonal loss, and therefore may well be the potential therapy for the treatment of MS. © 2007 Elsevier B.V. All rights reserved.